New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For VVUS;JNJ;AZN;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
February 23, 2015
12:53 EDTAZNAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
07:55 EDTAZNJefferies says other bidders may emerge for Salix
Jefferies says it could envision other bidders emerging for Salix (SLXP) and points out recent media reports have suggested Shire (SHPG) and Endo (ENDP) have considered making a bid for the company. It lists AstraZeneca (AZN) and Takeda as others who could have possible interest in Salix. The firm believes Valeant (VRX) could afford to pay more for Salix should other bidders emerge.
February 22, 2015
12:51 EDTJNJJ&J considers Cordis sale with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 20, 2015
17:31 EDTJNJJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
16:03 EDTJNJOptions Update; February 20, 2015
Subscribe for More Information
10:33 EDTPFEBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
10:31 EDTPFEPfizer announces FDA acceptance of NDA for Rapamune
Pfizer announced that the FDA has accepted for priority review a supplemental New Drug Application for RAPAMUNE for the treatment of lymphangioleiomyomatosis, a rare, progressive lung disease in women of childbearing age that is often fatal. With the Priority Review designation for the sNDA, Pfizer anticipates a decision in June of 2015 based on the anticipated Prescription Drug User Fee Act action date. The sNDA is based on results from the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial. The MILES Trial included 89 LAM patients with moderate lung impairment who were randomized to receive RAPAMUNE or placebo for 12 months, followed by a 12 month observation period. In the trial, those treated with RAPAMUNE for one year experienced stabilization of lung function as measured by forced expiratory volume in one second.
09:38 EDTJNJActive equity options trading on open
Subscribe for More Information
07:23 EDTJNJ, AZN, PFEAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTAZNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
18:25 EDTPFEPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
14:49 EDTPFEWalgreens selected by Pfizer as one of pharmacies to dispense Ibrance
Subscribe for More Information
07:12 EDTPFEWharton Health Care Club to hold a conference
Subscribe for More Information
February 18, 2015
16:46 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
12:36 EDTJNJAnalysts applaud cheaper than expected Boston Scientific settlement
Subscribe for More Information
12:31 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
07:41 EDTJNJSettlement 'a big win' for Boston Scientific, says Bernstein
Subscribe for More Information
07:12 EDTJNJBoston Scientific settlement should remove overhang, says Stifel
Subscribe for More Information
07:09 EDTJNJBoston Scientific payment to J&J well below expectations, says Piper Jaffray
Subscribe for More Information
February 17, 2015
17:16 EDTAZNActavis confirms temporary injunction related to generic Pulmicort RESPULES
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use